Title:
USES OF OPG LIGAND TO MODULATE IMMUNE RESPONSES
Document Type and Number:
WIPO Patent Application WO2002076507
Kind Code:
A3
Abstract:
Methods of stimulating or inhibiting activity of monocytes using OPG ligand, or other agonists or antagonists, are provided. Methods of treating pathological conditions, particularly immune related conditions, using such OPG ligand, agonists or antagonists are further provided. Agonists and antagonists contemplated for use in the invention include anti-RANK receptor antibodies, anti-OPG ligand antibodies, anti-OPG receptor antibodies, RANK receptor immunoadhesins, and OPG receptor immunoadhesins.
Inventors:
GREWAL IQBAL (US)
Application Number:
PCT/US2002/001238
Publication Date:
February 12, 2004
Filing Date:
February 06, 2002
Export Citation:
Assignee:
GENENTECH INC (US)
GREWAL IQBAL (US)
GREWAL IQBAL (US)
International Classes:
A61K38/00; A61K39/395; A61P1/04; A61P3/10; A61P17/06; A61P19/00; A61P19/02; A61P29/00; A61P31/00; A61P37/00; A61P37/02; C12N15/09; A61P37/06; A61P37/08; C07K14/705; C12N5/06; C12N5/08; A61K48/00; (IPC1-7): C12N5/06; C12N5/08; C12P21/02; A61K38/17; A61K48/00; A61K39/395; C07K14/705; A61P19/00; A61P29/00; A61P37/02
Other References:
ANDERSON ULF ET AL: "High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 4, 21 August 2000 (2000-08-21), pages 565 - 570, XP002233473, ISSN: 0022-1007
KONG Y Y ET AL: "Molecular control of bone remodeling and osteoporosis.", EXPERIMENTAL GERONTOLOGY. ENGLAND OCT 2000, vol. 35, no. 8, October 2000 (2000-10-01), pages 947 - 956, XP002233423, ISSN: 0531-5565
KONG Y-Y ET AL: "Osteoprotegerin ligand: a regulator of immune responses and bone physiology", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 10, 1 October 2000 (2000-10-01), pages 495 - 502, XP004217459, ISSN: 0167-5699
SUDA T ET AL: "The molecular basis of osteoclast differentiation and activation.", NOVARTIS FOUNDATION SYMPOSIUM. ENGLAND 2001, vol. 232, 2001, pages 235 - 247;discussion 247 - 250, XP008014375
GARDNEROVA M ET AL: "The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents.", CURRENT DRUG TARGETS. NETHERLANDS DEC 2000, vol. 1, no. 4, December 2000 (2000-12-01), pages 327 - 364, XP008014381, ISSN: 1389-4501
KONG Y Y ET AL: "Molecular control of bone remodeling and osteoporosis.", EXPERIMENTAL GERONTOLOGY. ENGLAND OCT 2000, vol. 35, no. 8, October 2000 (2000-10-01), pages 947 - 956, XP002233423, ISSN: 0531-5565
KONG Y-Y ET AL: "Osteoprotegerin ligand: a regulator of immune responses and bone physiology", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 10, 1 October 2000 (2000-10-01), pages 495 - 502, XP004217459, ISSN: 0167-5699
SUDA T ET AL: "The molecular basis of osteoclast differentiation and activation.", NOVARTIS FOUNDATION SYMPOSIUM. ENGLAND 2001, vol. 232, 2001, pages 235 - 247;discussion 247 - 250, XP008014375
GARDNEROVA M ET AL: "The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents.", CURRENT DRUG TARGETS. NETHERLANDS DEC 2000, vol. 1, no. 4, December 2000 (2000-12-01), pages 327 - 364, XP008014381, ISSN: 1389-4501
Download PDF: